A5032787628- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Breast Implant and Reconstruction
- Cancer and Skin Lesions
- Salivary Gland Tumors Diagnosis and Treatment
- MRI in cancer diagnosis
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Medical Imaging Techniques and Applications
- Cancer Diagnosis and Treatment
- Lymphatic System and Diseases
- Parathyroid Disorders and Treatments
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Global Cancer Incidence and Screening
- BRCA gene mutations in cancer
- AI in cancer detection
- Vitamin D Research Studies
- Vascular Tumors and Angiosarcomas
- Cancer survivorship and care
- Cardiac tumors and thrombi
- Pituitary Gland Disorders and Treatments
Case Western Reserve University
2022-2024
University Hospitals of Cleveland
2022-2024
University School
2022-2024
Ohio University
2022-2023
University Hospitals Seidman Cancer Center
2023
University of Kansas Medical Center
2015-2023
University of Kansas
2017-2022
The University of Texas MD Anderson Cancer Center
2020
The University of Kansas Cancer Center
2018-2020
University Medical Center
2020
Abstract Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness anthracycline-free platinum combinations TNBC is not well known. Here, we report efficacy NA + docetaxel (CbD) TNBC. Experimental Design: The study population includes 190 patients with stage I–III treated uniformly on two independent prospective cohorts. All were...
Abstract Purpose: Prognostic value of pathologic complete response (pCR) and extent attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) overall (OS) according to degree patients treated carboplatin docetaxel NAC. Patients Methods: One-hundred ninety stage I–III TNBC were (AUC6) (75 mg/m2) every 21 days × 6 cycles. pCR (no evidence invasive tumor axilla) Residual...
Abstract Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim the NeoSTOP multisite randomized phase II trial was assess efficacy anthracycline-free anthracycline-containing neoadjuvant regimens. Patients Methods: aged ≥18 years with stage I–III TNBC were (1:1) receive either paclitaxel (P) weekly × 12 AUC6 every 21 days 4 followed...
505 Background: Ribociclib (R) + letrozole (L) is superior to L in metastatic breast cancer (BC). Preoperative endocrine prognostic index (PEPI) score 0 after neoadjuvant therapy (NET) associated with low risk of relapse without chemotherapy ER+ BC. On-therapy change Ki-67 predicts adjuvant recurrence. FELINE a biomarker-based multicenter randomized trial comparing changes and PEPI between L+ Placebo (P) & L+R. Methods: Postmenopausal women >2 cm or node+ HER2- BC were 1:1:1 L+P, L+R...
Due to widespread adoption of screening mammography, there has been a significant increase in new diagnoses ductal carcinoma situ (DCIS). However, DCIS prognosis remains unclear. To address this gap, we developed an vivo model, Mouse-INtraDuctal (MIND), which patient-derived epithelial cells are injected intraductally and allowed progress naturally mice. Similar human DCIS, the cancer formed lesions inside mouse mammary ducts mimicked all histologic subtypes including micropapillary,...
Breast magnetic resonance imaging (MRI) delineates disease extent sensitively in newly diagnosed breast cancer patients, but improved outcomes are uncertain. Young women, for whom mammography is less sensitive, expected to benefit from MRI-based resection. We identified 512 women aged ≤50 years, undergoing breast-conserving treatment (BCT: tumor-free resection margins and radiotherapy) during 2006-2013 through Northwestern Medicine database queries; 64.5% received preoperative MRI 35.5% did...
Genomic instability can promote inflammation and tumor development. Previous research revealed an unexpected layer of regulation genomic by a cytoplasmic protein MYO10; however, the underlying mechanism remained unclear. Here, we report stability-mediated mitotic MYO10 in controlling genome stability. We characterized degron motif phosphorylation residues that mediate β-TrCP1-dependent degradation. The level phosphorylated transiently increases during mitosis, which is accompanied...
Oral tamoxifen citrate benefits women with ductal carcinoma in situ (DCIS), but concern about toxic effects has limited acceptance. Previous pilot studies have suggested transdermal 4-hydroxytamoxifen gel equivalent antiproliferative efficacy to oral tamoxifen, low systemic exposure.
One common adverse effect following breast-conservation surgery and adjuvant radiation is lymphedema. While lymphedema of the arm has been well-characterized, there less investigation into breast. We sought to characterize rates breast (BLE) in women with early-stage cancer identify potential predictors its development. Two hundred thirty consecutive patients treated lumpectomy whole therapy (WBRT) from January 2016 - June 2017 were included. All seen our monitoring clinic for baseline at...
Small invasive breast cancers (BCs) with tumor sizes ≤5 mm (T1a) are associated an excellent prognosis without systemic therapy. Although HER2 overexpression (HER2+) is a higher risk of recurrence and poorer clinical outcomes, in the absence directed therapy, it remains unclear whether adjuvant therapy necessary node-negative patients diagnosed HER2+ BCs (pT1aN0M0).The National Cancer Database was searched to identify pT1aN0M0 from 2004 2017. The cohort stratified by treatment status: local...
The RxPONDER trial found that among breast cancer patients with estrogen receptor positive (ER+) cancer, 1-3 axillary nodes, and a recurrence score of ≤25, only pre-menopausal women benefitted from adjuvant chemoendocrine therapy; postmenopausal similar characteristic did not benefit chemotherapy. We aimed to replicate the RxPonder using larger patient cohort real world data determine whether RS threshold existed where chemotherapy was beneficial regardless age.The National Cancer Database...
Background: PREDICT is an online prognostication tool derived from breast cancer registry information on approximately 6,000 women treated in the United Kingdom that estimates postsurgical treatment benefit of surgery alone, chemotherapy, trastuzumab, endocrine therapy, and/or adjuvant bisphosphonates early-stage cancer. Our aim was to validate algorithm predicting 5- and 10-year overall survival (OS) probabilities using real-world outcomes among US patients with Methods: A retrospective...
516 Background: Addition of neoadjuvant carboplatin (Cb) to paclitaxel (T) followed by doxorubicin + cyclophosphamide (AC) improves pathologic complete response (pCR) rate compared T/AC in TNBC. An anthracycline-free regimen Cb plus docetaxel (D) also yields high pCR rates TNBC, and patients achieving with this demonstrate excellent 3-year outcomes without adjuvant anthracycline. This study was designed compare the efficacy regimens CbT→AC CbD Methods: In multicenter study, eligible stage...